{
    "Trade/Device Name(s)": [
        "Sure-Screen Amphetamine",
        "Sure-Screen Benzodiazepine",
        "Sure-Screen Methamphetamine",
        "Sure-Screen Methadone",
        "Sure-Screen Opiate",
        "Sure-Screen Phencyclidine",
        "Sure-Screen Cannabinoids",
        "Sure-Screen Cocaine"
    ],
    "Submitter Information": "Medtox Diagnostics, Inc.",
    "510(k) Number": "K050394",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DKZ",
        "JXM",
        "LDJ",
        "DIO",
        "DJR",
        "DJC",
        "DJG",
        "LCM"
    ],
    "Summary Letter Date": "October 25, 2005",
    "Summary Letter Received Date": "September 1, 2005",
    "Submission Date": "August 31, 2005",
    "Regulation Number(s)": [
        "21 CFR 862.3100"
    ],
    "Regulation Name(s)": [
        "Amphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamines (d-Amphetamine)",
        "Benzodiazepines (Nordiazepam)",
        "Cocaine (Benzoylecgonine)",
        "Methamphetamine (d-Methamphetamine)",
        "Methadone",
        "Opiates (Morphine)",
        "Phencyclidine",
        "THC (11-nor-9-carboxy-\u03949 THC)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic test strip"
    ],
    "Methodologies": [
        "Preliminary analytical test",
        "Qualitative detection"
    ],
    "Submission Type(s)": [
        "Test System"
    ],
    "Document Summary": "FDA 510(k) summary for Medtox Sure-Screen Drugs of Abuse immunochromatographic test system for rapid qualitative detection of amphetamines, benzodiazepines, cocaine, methamphetamine, methadone, opiates, phencyclidine, and cannabinoids in human urine.",
    "Indications for Use Summary": "Qualitative, rapid detection of specified drugs of abuse in human urine for prescription point-of-care use in settings such as workplace, criminal justice, drug rehabilitation, physician offices, and laboratories; not for over-the-counter sale.",
    "fda_folder": "Toxicology"
}